Related Experiment Videos
Losigamone add-on therapy in partial epilepsy: a placebo-controlled study
1Department of Epileptology, University of Bonn, Germany, Dr Willmar Schwabe GmbH, Karlsruhe, Germany.
Acta Neurologica Scandinavica
|May 1, 2001
Summary
Losigamone (LSG) effectively reduced chronic partial seizures in a clinical trial. This anticonvulsant demonstrated good tolerability, offering a promising treatment option for epilepsy patients.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Epilepsy management requires effective and well-tolerated anticonvulsant therapies.
- Chronic partial seizures present a significant therapeutic challenge.
Purpose of the Study:
- To assess the efficacy and tolerability of losigamone (LSG) as an add-on treatment for chronic partial seizures.
Main Methods:
- A double-blind, placebo-controlled study involved 203 patients with chronic partial seizures.
- Patients received either 3x500 mg losigamone (LSG) daily or a placebo as add-on therapy.
Main Results:
- Losigamone (LSG) showed a statistically significant reduction in seizure frequency compared to placebo (median percent change: 14.9% vs. 6.7%, P=0.004).
- A 50% reduction in seizure frequency was observed in 22.3% of LSG-treated patients versus 14.6% of placebo patients (P=0.13).
- Adverse events were more frequent with LSG (59.6%) than placebo (37.5%), primarily mild to moderate CNS-related side effects.
Conclusions:
- Losigamone (LSG) is an effective anticonvulsant for treating chronic partial seizures.
- The drug is generally well-tolerated, supporting its potential clinical use.